Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: An experience-based review

American Heart Journal

Volumn 157, Issue 4, 2009, Pages 625-635

  Oudiz, Ronald J ^a   Farber, Harrison W ^b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTACYCLIN; PROSTANOID; UNIPROST;

CARDIOPULMONARY HEMODYNAMICS; CLINICAL PRACTICE; CLINICAL TRIAL; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DYSPNEA; EXERCISE; FLUSHING; HEADACHE; HUMAN; IMMUNITY; JAW PAIN; LONG TERM CARE; NAUSEA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; SHORT COURSE THERAPY; SIDE EFFECT; UNITED STATES;

DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERTENSION, PULMONARY; INJECTIONS, INTRAVENOUS; PROSTAGLANDINS; PULMONARY WEDGE PRESSURE; TREATMENT OUTCOME;

EID: 62949168280     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.10.029     Document Type: Review

References (51)

1. Farber H.W., and Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 351 (2004) 1655-1665
2. Rich S. Pulmonary hypertension. In: Braunwald E., Libby P., and Zipes D.P. (Eds). Heart disease: a textbook of cardiovascular medicine (2001), WB Saunders, Philadelphia (Pa) 1912-1929
3. McLaughlin V.V., and McGoon M.D. Pulmonary arterial hypertension. Circulation 114 (2006) 1417-1431
4. D'Alonzo G.E., Barst R.J., Ayres S.M., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115 (1991) 343-349
5. Koh E.T., Lee P., Gladman D.D., and Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 35 (1996) 989-993
6. Christman B.W., McPherson C.D., Newman J.H., et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327 (1992) 70-75
7. Tuder R.M., Cool C.D., Geraci M.W., et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 159 (1999) 1925-1932
8. Baumhakel M., Cremers B., and Bohm M. Current therapy of pulmonary hypertension. Herz 30 (2005) 303-310
9. Coquette A., Boeynaems J.M., and Vray B. Eicosanoids modulate CR1- and Fc-dependent bacterial phagocytosis. Eur J Pharmacol 226 (1992) 1-4
10. Rubin L.J., Mendoza J., Hood M., et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 112 (1990) 485-491
11. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334 (1996) 296-301
12. Badesch D.B., Tapson V.F., McGoon M.D., et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132 (2000) 425-434
13. Barst R.J., Rubin L.J., McGoon M.D., et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 121 (1994) 409-415
14. Shapiro S.M., Oudiz R.J., Cao T., et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 30 (1997) 343-349
15. McLaughlin V.V., Shillington A., and Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 106 (2002) 1477-1482
16. Sitbon O., Humbert M., Nunes H., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 40 (2002) 780-788
17. Kuhn K.P., Byrne D.W., Arbogast P.G., et al. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 167 (2003) 580-586
18. McLaughlin V.V., Genthner D.E., Panella M.M., et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 338 (1998) 273-277
19. Flolan [package insert] (2007), Gilead Colorado, Westminster (Colo)
20. Badesch D.B., Abman S.H., Simonneau G., Rubin L.J., and McLaughlin V.V. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 131 (2007) 1917-1928
21. Galie N., Torbicki A., Barst R., et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 25 (2004) 2243-2278
22. Wade M., Baker F.J., Roscigno R., et al. Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion. J Clin Pharmacol 44 (2004) 83-88
23. Laliberte K., Arneson C., Jeffs R., et al. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol 44 (2004) 209-214
24. Simonneau G., Barst R.J., Galie N., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 165 (2002) 800-804
25. Lang I., Gomez-Sanchez M., Kneussl M., et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest 129 (2006) 1636-1643
26. Barst R.J., Galie N., Naeije R., et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 28 (2006) 1195-1203
27. McLaughlin V.V., Gaine S.P., Barst R.J., et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 41 (2003) 293-299
28. Tapson V.F., Gomberg-Maitland M., McLaughlin V.V., et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 129 (2006) 683-688
29. Gomberg-Maitland M., Tapson V.F., Benza R.L., et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 172 (2005) 1586-1589
30. Remodulin [package insert] (2006), United Therapeutics Corp, Research Triangle Park (NC)
31. Narumiya S., Sugimoto Y., and Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 79 (1999) 1193-1226
32. Kiriyama M., Ushikubi F., Kobayashi T., et al. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 122 (1997) 217-224
33. Katsuyama M., Ikegami R., Karahashi H., et al. Characterization of the LPS-stimulated expression of EP2 and EP4 prostaglandin E receptors in mouse macrophage-like cell line, J774.1. Biochem Biophys Res Commun 251 (1998) 727-731
34. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension-seven sites, United States, 2003-2006. MMWR Morb Mortal Wkly Rep 56 (2007) 170-172
35. Fischer M., Bhatnagar J., Guarner J., et al. Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion. N Engl J Med 353 (2005) 2352-2360
36. Nalesnik J.G., Jones L., and Kraus S.R. Group B streptococcal septicemia following intracavernous injection therapy for erectile dysfunction in diabetes. J Urol 172 (2004) 151-152
37. Dumble L.J., Gibbons S., Tejpal N., et al. 15 AU81, a prostacyclin analog, potentiates immunosuppression and mitigates renal injury due to cyclosporine. Transplantation 55 (1993) 1124-1128
38. Aronoff D.M., Peres C.M., Serezani C.H., et al. Synthetic prostacyclin analogs differentially regulate macrophage function via distinct analog-receptor binding specificities. J Immunol 178 (2007) 1628-1634
39. Oudiz R.J., Widlitz A., Beckmann X.J., et al. Micrococcus-associated central venous catheter infection in patients with pulmonary arterial hypertension. Chest 126 (2004) 90-94
40. Miller NS, Dobre MC, Liebschutz J, et al. Micrococcus bacteremia in a patient with pulmonary hypertension and long-term central venous catheter. Opportunity knocks and an unexpected pathogen enters. Clinical Microbiology Newsletter 2007;29:173-5.
41. Reisbig K.A., Coffman P.A., Floreani A.A., et al. Staggered transition to epoprostenol from treprostinil in pulmonary arterial hypertension. Ann Pharmacother 39 (2005) 739-743
42. Robbins I.M., Christman B.W., Newman J.H., et al. A survey of diagnostic practices and the use of epoprostenol in patients with primary pulmonary hypertension. Chest 114 (1998) 1269-1275
43. Rich S., and McLaughlin V.V. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 34 (1999) 1184-1187
44. Kerbaul F., Brimioulle S., Rondelet B., et al. How prostacyclin improves cardiac output in right heart failure in conjunction with pulmonary hypertension. Am J Respir Crit Care Med 175 (2007) 846-850
45. Sandifer B.L., Brigham K.L., Lawrence E.C., et al. Potent effects of aerosol compared with intravenous treprostinil on the pulmonary circulation. J Appl Physiol 99 (2005) 2363-2368
46. Skoro-Sajer N., Bonderman D., Wiesbauer F., et al. Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension. J Thromb Haemost 5 (2007) 483-489
47. Steffen R.P., and de la Mata M. The effects of I5AU8I, a chemically stable prostacyclin analog, on the cardiovascular and renin-angiotensin systems of anesthetized dogs [corrected]. Prostaglandins Leukot Essent Fatty Acids 43 (1991) 277-286
48. Highland K.B., Strange C., Mazur J., et al. Treatment of pulmonary arterial hypertension: a preliminary decision analysis. Chest 124 (2003) 2087-2092
49. Morrow L., Malesker M.A., and Tilleman J.A. Management of pulmonary arterial hypertension. US Pharm 10 (2005) HS18-HS38
50. Narine L., Hague L.K., Walker J.H., et al. Cost-minimization analysis of treprostinil vs. epoprostenol as an alternate to oral therapy non-responders for the treatment of pulmonary arterial hypertension. Curr Med Res Opin 21 (2005) 2007-2016
51. Einarson T.R., Granton J.T., Vicente C., et al. Cost-effectiveness of treprostinil versus epoprostenol in patients with pulmonary arterial hypertension: a Canadian analysis. Can Respir J 12 (2005) 419-425